Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma

Leukemia and Lymphoma

Volumn 41, Issue 3-4, 2001, Pages 387-395

  Mitterer, M ^a   Lanthaler, A J ^a   Schnabel, B ^a   Svaldi, M ^a   Oduncu, F ^a   Coser, P ^a   Emmerich, B ^a   Huemer, H ^a   Straka, C ^a  

^a Bone Marrow Transplantation ^*  (Italy)

Author keywords

Multiple myeloma; Myeloma precursor cells; Negative selection; Purging

Indexed keywords

B LYMPHOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; CANCER RECURRENCE; CELL SELECTION; CONTROLLED STUDY; HUMAN; INFUSION; LEUKAPHERESIS; LYMPHOCYTE CLONE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL LYMPHOCYTE; PLASMA CELL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROLYMPHOCYTE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STATISTICS; STEM CELL; STEM CELL TRANSPLANTATION; SURVIVAL;

EID: 0034992828     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109057994     Document Type: Article

References (36)

1. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in Multiple myeloma
2. Superiority of tandem autologous transplantation over standard therapy for previously un treated multiple myeloma
3. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
4. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy
5. The hematopoetic stem cell antigen CD34, is not expressed on the malignant cells in multiple myeloma
6. CD34+ cells in the blood of patients with multiple myeloma express CD 19 and IgH m RNA and have patient specific IgH VDJ gene rearrangements
7. Expression of the hematopoetic stem cell antigen CD34 on blood and bone marrow monoclonal plasmacells from patients with multiple myeloma
8. Transplantation of CD 34 peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma
9. CD34 selections from myeloma peripheral blood cell autografts contain residual tumor cells due to impurity, not to CD34 + myeloma cells
10. Purified CD34 + Lin - Thy+ stem cells do not contain clonal myeloma cells
11. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain
12. Circulating clonotypic B-cells in the biology of myeloma. Speculations on the origin of multiple myeloma
13. Autologous bone marrow transplantation for myeloma patients using PNA- and CD19 purged marrow rescue
14. Monoclonal antibody purged bone marrow transplantation therapy for multiple myeloma
15. Monoclonal antibody purged autologous bone marrow transplantation therapy for multiple myeloma
16. Detection of monoclonal myeloma precursor B cells in peripheral blood progenitor cell harvests and their relationship to the clinical outcome multiple myeloma patients
17. Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high dose chemotherapy and rh G-CSF
18. Assessment of IgH PCR strategies in multiple myeloma
19. Detection and accurate sizing of PCR product by automated scanning: Improved detection of immunoglobulin gene rearrangement in ALL
20. A reliable approach for sequencing clone specific CDRIII regions in B-cell lymphoma
21. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma
22. Detection of monoclonal plasmacells in the peripheral blood stem cell harvests of patients with multiple myeloma
23. Monoclonal plasmacells in the peripheral blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse free survival after transplantation
24. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma
25. Circulating clonal lymphocytes in myeloma constitue a minor subpopulation of B cells
26. Hyaluronan dependent motility of B-cells and leukemic plasma cells but not of bone marrow plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44
27. RHAMM, a receptor for hyaluronan mediated motility, on normal lymphocytes, thymocytes and in B-cell malignancy: A mediator in B-cell malignancy?
28. High dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvest and after autografting
29. Circulating monoclonal B-cells expressing P glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma
30. CD19 selection improves the sensitivity of B cell lymphoma detection
31. The relationship between monoclonal myeloma precursor B-cells in the peripheral blood progenitor cell harvest and the clinical outcome of multiple myeloma patients
32. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
33. +-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: Tumour cell contamination and outcome
34. Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma
35. Autologous transplantation with tumor free graft: A model for multiple myeloma patient
36. Myeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice